The outcome ofancy. COVID-19 in patients with hematological malign.
作者信息
Yigenoglu Tugce N, Bascı Semih, Dal Mehmet S, Korkmaz Serdal, Turgut Burhan, Altuntas Fevzi
机构信息
Department of Hematology and Bone Marrow Transplantation Center, Ankara Oncology Training and Research Hospital, University of Health Sciences, Ankara, Turkey.
Department of Hematology, Kayseri Training and Research Hospital, University of Health Sciences, Kayseri, Turkey.
出版信息
J Med Virol. 2021 Mar;93(3):1255. doi: 10.1002/jmv.26607. Epub 2020 Nov 1.
Abstract
摘要
相似文献
1
The outcome ofancy. COVID-19 in patients with hematological malign.血液系统恶性肿瘤患者中新冠病毒病的结局。
J Med Virol. 2021 Mar;93(3):1255. doi: 10.1002/jmv.26607. Epub 2020 Nov 1.
2
Managing patients with hematological malignancies during COVID-19 pandemic.在新冠疫情期间管理血液系统恶性肿瘤患者
Expert Rev Hematol. 2020 Aug;13(8):787-793. doi: 10.1080/17474086.2020.1787147. Epub 2020 Jul 12.
3
Strategic plan for management of COVID-19 in paediatric haematology and oncology departments.儿科血液学和肿瘤学部门新冠病毒病管理战略计划
Lancet Haematol. 2020 May;7(5):e359-e362. doi: 10.1016/S2352-3026(20)30104-6. Epub 2020 Apr 1.
4
The outcome of COVID-19 in patients with hematological malignancy.血液系统恶性肿瘤患者的新冠病毒病结局
J Med Virol. 2021 Mar;93(3):1229. doi: 10.1002/jmv.26576. Epub 2020 Oct 10.
5
SARS-CoV-2 infection and mortality in pediatric patients with hematological malignancies and solid tumors.血液系统恶性肿瘤和实体瘤儿科患者中的新型冠状病毒2型感染及死亡率
Pediatr Hematol Oncol. 2023 May;40(4):429-432. doi: 10.1080/08880018.2022.2120937. Epub 2022 Sep 12.
6
Severe COVID-19 in patients with hematological cancers presenting with viremia.血液系统癌症患者出现病毒血症的重症 COVID-19。
Ann Oncol. 2021 Oct;32(10):1297-1300. doi: 10.1016/j.annonc.2021.07.002. Epub 2021 Jul 13.
7
Balancing risk and benefit during coronavirus.在新冠疫情期间权衡风险与收益。
Blood. 2020 May 21;135(21):1817. doi: 10.1182/blood.2020006279.
8
COVID-19 in patients with hematological malignancies: A retrospective case series.血液系统恶性肿瘤患者中的新型冠状病毒肺炎：一项回顾性病例系列研究。
Int J Lab Hematol. 2020 Dec;42(6):e256-e259. doi: 10.1111/ijlh.13301. Epub 2020 Aug 4.
9
Clinical characteristics, therapeutic management, and prognostic factors of adult COVID-19 inpatients with hematological malignancies.成人血液病恶性肿瘤合并 COVID-19 住院患者的临床特征、治疗管理和预后因素。
Leuk Lymphoma. 2020 Dec;61(14):3440-3450. doi: 10.1080/10428194.2020.1808204. Epub 2020 Aug 25.
10
Outcome of hospitalized patients with hematological malignancies and COVID-19 infection in a large urban healthcare trust in the United Kingdom.英国一家大型城市医疗信托机构中血液系统恶性肿瘤合并新型冠状病毒肺炎感染住院患者的结局
Leuk Lymphoma. 2021 Feb;62(2):469-472. doi: 10.1080/10428194.2020.1838506. Epub 2020 Nov 9.
引用本文的文献
1
What Do We Currently Know About Chronic Myeloid Leukemia (CML) and COVID-19?目前我们对慢性髓性白血病（CML）和 COVID-19 了解多少？
Curr Oncol Rep. 2022 May;24(5):645-650. doi: 10.1007/s11912-021-01169-w. Epub 2022 Feb 26.
2
Low symptomatic COVID-19 in an elderly patient with follicular lymphoma treated with rituximab-based immunotherapy: A case report.利妥昔单抗为基础的免疫疗法治疗滤泡性淋巴瘤老年患者的低症状性新型冠状病毒肺炎：一例报告
World J Clin Cases. 2021 Jun 26;9(18):4859-4865. doi: 10.12998/wjcc.v9.i18.4859.
Zotero 插件